Gilead Sciences’ (GILD) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD)‘s stock had its “neutral” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $70.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential downside of 15.71% from the stock’s previous close.

Several other equities analysts also recently commented on GILD. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Piper Sandler restated an “overweight” rating and issued a $95.00 price target on shares of Gilead Sciences in a report on Wednesday, September 11th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. BMO Capital Markets boosted their price target on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Robert W. Baird restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Twelve analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $82.06.

Gilead Sciences Trading Down 0.1 %

GILD stock opened at $83.05 on Monday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm’s fifty day simple moving average is $76.09 and its two-hundred day simple moving average is $71.00. The stock has a market capitalization of $103.47 billion, a price-to-earnings ratio of 230.69, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. As a group, analysts anticipate that Gilead Sciences will post 3.78 earnings per share for the current year.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,002,940 over the last 90 days. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 238 shares during the last quarter. Sachetta LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at $30,000. Palisade Asset Management LLC acquired a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Frank Rimerman Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $36,000. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.